Anne Prener

Cellinta Ltd. operates as a biotechnology firm. The company was founded on August 16, 2019 and is headquartered in Reading, the United Kingdom.

Imbria Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing novel therapies that restore cellular energy deficits. It focuses on restoring or improving the cell?s ability to produce energy where energy imbalances are at the root of disease, including cardiovascular diseases and inborn errors of metabolism. The company was founded by Andrew Levin and David-Alexandre C. Gros in 2018 and is headquartered in Boston, MA.

SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London.

Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom.

Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom.

Novo Nordisk A/S (CO: NOVO.B; NYSE: NVO), a Danish healthcare company which manufactures and markets pharmaceutical products and services worldwide, invests through their corporate venture fund NNBF-Novo Nordisk Biotech Fund (NNBF). Based in Bagsværd near Copenhagen, NNBF is a business unit within Novo Nordisk A/S, responsible for the company's venture capital activities. Investments are made on the books of Novo Nordisk A/S out of internal financial resources. NNBF is managed as an evergreen fund.